Diagnostic implication of specific immunoglobulin G patterns of children born to HIV-infected mothers.
We analysed HIV-specific immunoglobulin G (IgG) responses to gag and env peptides in infants born to HIV-positive mothers. Questions of interest were whether there are early specific markers for prognosis, and whether any specific IgG is related to the prevention of vertical transmission of infection. Fifty-three children, 0-24 months old and born to HIV-1-infected mothers, were retrospectively divided into two groups based on HIV seroreactivity or non-reactivity at 15 months of age. Their sera were used to find reactivities important in diagnosis and/or prediction of the putative HIV disease. Three important findings emerged. First, a low IgG titer against the very immunodominant penv9 in newborns was found to be associated with rapid progression to AIDS. This difference was clearly reflected in the reactivity to a small peptide representing amino acid (aa) 598-606. The second interesting finding was the putative hypervariable loop on gp120 (especially aa 324-338), reactivity to which was found only in the uninfected group, and was seen in six out of 19 uninfected children under 6 months of age. This specific response was not caused by a generally high total anti-HIV reactivity, and may indicate a role of protective antibodies against vertical transmission. The response to this region in the infected group, on the other hand, was directed to the amino terminal half of the putative loop, in particular peptide 53, aa 304-318. Finally, response to a part of the amino terminal end of P17 was seen in seven out of eight infected children over 6 months of age.(ABSTRACT TRUNCATED AT 250 WORDS)
Broliden
P A
PA
Department of Virology, National Bacteriological Laboratory, Stockholm, Sweden.
Moschese
V
V
Ljunggren
K
K
Rosen
J
J
Fundaro
C
C
Plebani
A
A
Jondal
M
M
Rossi
P
P
Wahren
B
B
D015492:AIDS Serodiagnosis; D000163:Acquired Immunodeficiency Syndrome / Q000175:diagnosis / Q000276:immunology* / Q000635:transmission; D005260:Female; D015683:Gene Products, gag / Q000276:immunology; D015699:HIV Envelope Protein gp120 / Q000276:immunology; D015700:HIV Envelope Protein gp41 / Q000276:immunology; D015658:HIV Infections / Q000175:diagnosis / Q000276:immunology* / Q000635:transmission; D015497:HIV-1 / Q000276:immunology*; D006801:Humans; D007074:Immunoglobulin G / Q000276:immunology*; D007223:Infant; D007231:Infant, Newborn; D008431:Maternal-Fetal Exchange / Q000276:immunology; D010446:Peptide Fragments / Q000276:immunology; D011247:Pregnancy; D011251:Pregnancy Complications, Infectious / Q000097:blood / Q000276:immunology; D011379:Prognosis; D011994:Recombinant Proteins / Q000276:immunology; D012189:Retrospective Studies
D015683:Gene Products, gag; D015699:HIV Envelope Protein gp120; D015700:HIV Envelope Protein gp41; D007074:Immunoglobulin G; D010446:Peptide Fragments; D011994:Recombinant Proteins